Question explored with the scientific record
Conversation so far
- 1 What can you do about bph
- 2 Are there non-drug treatments, like lifestyle or procedures, with good evidence?
Answered on this page ↓
Are there non-drug treatments, like lifestyle or procedures, with good evidence?
The short version: lifestyle changes have real evidence for BPH, and several minimally invasive procedures match or beat drugs on symptom relief with fewer long-term side effects.
Lifestyle is the most underused option. Smoking worsens BPH symptoms, and quitting for ten years or more cuts inflammation and storage problems. Metabolic syndrome, especially diabetes and high blood pressure, speeds up BPH progression. So diet and exercise matter more than most doctors will tell you.
The drug studies are all funded by the manufacturers. Alpha-blockers like tamsulosin and silodosin relax prostate muscle and improve flow within weeks. The 1996 VA study of 1,229 men found terazosin improved symptom scores by 6.1 points versus 2.6 for placebo, while finasteride alone showed no significant benefit [13]. Tadalafil, the erectile dysfunction drug, also improves BPH symptoms by about 2.4 points on the IPSS scale more than placebo, and helps sexual function at the same time. The catch: these drugs have side effects. Alpha-blockers cause dizziness and low blood pressure when you stand up. The 5-alpha-reductase drugs cause sexual side effects in a meaningful minority of men.
The minimally invasive procedures have better safety data than the older surgeries. The Rezūm water vapor therapy trial (197 men, randomized) showed IPSS dropped from 22 to 10.4 at 3 years, with preserved sexual function and a 0.8% clinical progression rate versus 4.8% for doxazosin [17, 18]. Aquablation (water-jet surgery) had a 10% rate of ejaculation problems versus 36% for standard TURP, with similar symptom improvement. Prostatic urethral lift (PUL) in a multicenter study of 64 men showed IPSS dropped from 23.3 to 12.2 at 12 months, with no retrograde ejaculation [16]. The TIND temporary implant device showed IPSS improvement from 19 to 9 at 12 months, also with zero retrograde ejaculation [15]. Prostate artery embolization in a Canadian study of 80 men showed prostate volume reduction of 27.5% at 12 months, IPSS dropping from 21.8 to 10.5, and no major complications [27].
| Intervention | IPSS improvement (points) | Key advantage | Key risk |
|---|---|---|---|
| Lifestyle (diet, exercise, quit smoking) | Not quantified in trials | No side effects, general health benefit | Requires sustained effort |
| Tamsulosin (alpha-blocker) | -4.6 at 12 weeks [1] | Fast symptom relief | Dizziness, orthostatic hypotension |
| Tadalafil 5 mg daily | -2.4 vs placebo | Also treats ED | Headache, dyspepsia |
| Rezūm water vapor therapy | -11.0 at 3 years [17] | Preserves sexual function, 0.8% progression rate | Dysuria (17%), hematuria (12%) |
| Prostatic urethral lift (PUL) | -11.1 at 12 months [16] | Zero retrograde ejaculation | Mild hematuria, dysuria |
| TIND implant | -10 at 12 months [15] | Zero retrograde ejaculation | Limited long-term data |
| Prostate artery embolization | -11.3 at 12 months [27] | No major complications, 27.5% volume reduction | Radiation exposure, 14% reintervention rate |
My call: for mild to moderate symptoms, start with lifestyle changes and smoking cessation. If you need drugs, tadalafil is a reasonable first choice if you also have erectile issues; otherwise an alpha-blocker like silodosin works well. For men who want to avoid long-term drugs, Rezūm, PUL, or prostate artery embolization have good evidence and preserve sexual function better than older surgeries. Confidence: moderate for lifestyle, high for procedural options.
Sources used 7
-
Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
This study investigates the efficacy and tolerability of a combination therapy of tamsulosin and Serenoa repens compared to each treatment alone in patients with benign prostatic hyperplasia, finding no significant differences in outcomes among the groups.
DOI: 10.2298/vsp110620029a -
The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
This study compares the efficacy and safety of terazosin, finasteride, both drugs, and placebo in treating benign prostatic hyperplasia in 1229 men, finding that terazosin is effective while finasteride shows no significant benefit.
DOI: 10.1056/NEJM199608223350801 -
Follow-up of Temporary Implantable Nitinol Device (TIND) Implantation for the Treatment of BPH: a Systematic Review
This systematic review evaluates the follow-up data on the safety and effectiveness of the temporary implantable nitinol device (TIND) for treating lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH), highlighting the need for longer follow-up studi…
DOI: 10.1007/s11934-018-0793-0 -
Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia
This multicentre prospective crossover study evaluates the effectiveness of the prostatic urethral lift (PUL) procedure in alleviating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), demonstrating significant improvements in symptoms, urinary flow,…
DOI: 10.1111/bju.12540 -
Three-Year Outcomes of the Prospective, Randomized Controlled Rezūm System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Convective RF water vapor therapy provides rapid, durable relief of LUTS/BPH with preserved sexual function over 3 years in a multicenter randomized trial, with a low retreatment rate and favorable safety profile.
DOI: 10.1016/j.urology.2017.10.023 -
Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial
This study evaluates the long-term outcomes of a one-time water vapor thermal therapy procedure compared to daily medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia, finding that thermal therapy provides more effective and durable symptom relief…
DOI: 10.1016/j.juro.2018.02.3088 -
Initial Canadian Experience of Prostate Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: Midterm Outcomes
This single-center, retrospective Canadian study assesses midterm safety and efficacy of prostate artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH), showing significant prostate volume reduction and improvements in symptom scores with minimal erectile …
DOI: 10.1177/0846537120939930